Safety topic
GLP-1 medications and gallbladder events (cholelithiasis)
Rapid weight loss of any kind increases gallstone risk; GLP-1 trials show ~1-3% incidence of cholelithiasis vs ~0.5% placebo. The risk is weight-loss mediated, not drug-specific.
Real, documented risk
Who should not take this
- Active acute cholecystitis
- Recent gallstone-induced pancreatitis (within 6 months)
How it happens
Rapid weight loss + reduced bile flow + altered cholesterol saturation create the classic gallstone-formation environment. STEP-1 (semaglutide) reported gallbladder-related adverse events in 2.6% of treated patients vs 1.2% placebo; SURMOUNT-1 (tirzepatide) reported 2.0% vs 0.4% placebo.
Red flags — when to seek care
- Persistent right-upper-quadrant pain
- Pain after fatty meals that lasts hours
- Yellowing of skin or eyes (jaundice)
- Fever with abdominal pain
What to do
- 1.Report persistent RUQ pain or post-meal pain to your prescriber
- 2.Standard workup is ultrasound + LFTs
- 3.Mitigation strategies: gradual weight loss (≤1-2 lb/week), maintained protein intake, occasional dietary fat (very-low-fat diets accelerate stone formation)
Affected medications
Sources
People also ask
Common questions readers ask
- Can you drink alcohol on Wegovy?
- No hard contraindication, but alcohol tolerance often drops sharply on GLP-1. Many patients also report reduced desire for alcohol — likely a secondary effect of GLP-1 on the brain reward system. Full evidence-graded answer
- Does GLP-1 affect oral birth control?
- Tirzepatide (Mounjaro, Zepbound) has documented reduced absorption of oral contraceptives during the first 4 weeks of each dose increase. Use backup contraception for ~4 weeks after starting + after each step-up. Semaglutide has no documented effect. Full evidence-graded answer
- Can I take GLP-1 while pregnant?
- No. All FDA-approved GLP-1s carry a pregnancy contraindication. Stop GLP-1 at least 2 months before planned conception due to its long half-life. Full evidence-graded answer
- Is it safe to take GLP-1 long-term?
- Liraglutide has 15+ years of post-marketing data (Victoza approved 2010). Semaglutide has 8+ years (Ozempic approved 2017). No new class-wide safety signals have emerged in extended follow-up. Chronic use is the FDA-approved indication for both T2D and obesity. Full evidence-graded answer
Editorial information based on FDA prescribing data + peer-reviewed sources as of 2026. Not personal medical advice. Reviewed by Jane Novak, MD, MPH.